Neuren: In trading halt pending clinical trial announcement

Company News

by Jessica Amir

Neuren Pharmaceuticals Limited (ASX:NEU) has entered into a trading halt pending an announcement about its lead product’s clinical trial.

The company which develops brain injury and disorder treatment requested the halt after the market closed on Friday.

The halt is expected to remain until Wednesday 22 March or until Neuren announces a statement about Phase 2 of its clinical trial in Rett syndrome, and how its lead product trofinetide is used.

The company says its already conducted double-blind placebo-controlled Phase 2 trials in both Rett syndrome and Fragile X syndrome and found benefit from their product, trofinetide.

Shares in Neuren Pharmaceuticals Limited (ASX:NEU) last traded flat on Friday at 8 cents.
 

Jessica Amir

Finance News Network
Jessica is a senior finance journalist and presents the Market Outlook, Market at Midday and Market Wrap. She also presents ASX company news and interviews CEOs. She joined FNN in January 2017 with six years of broadcast journalism experience. She worked as a journalist and producer with Sky News Business, ABC 1, ABC's The Business and ABC24. She also worked in regional Australia for Prime 7 and WIN News as a TV reporter. In her prior life she worked as a financial planner.